Casi obtains all rights related to CB-5339 novel VCP/p97 inhibitor

CASI Pharmaceuticals announced the execution of the Assignment Agreement with Cleave Therapeutics, pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the US CB-5339 Investigational New Drug, or IND, application. CB-5339 is an oral, second-generation, small molecule valosin-containing protein, or VCP, /p97 inhibitor, designed to disrupt protein homeostasis, DNA damage response and other cellular stress pathways. In a Phase 1 clinical trial in patients with acute myeloid leukemia and myelodysplastic syndrome, the drug was well tolerated in 55 patients and demonstrated signs of clinical activity. Two patients remain on CB-5339 under compassionate use protocols at two leading US cancer centers.